Celgene, among Acceleron’s strategic partners, and all other existing investors participated in this funding. The proceeds will be utilized to expand and advance Acceleron’s scientific stage pipeline also to continue to support its highly productive study engine.D., Chief Executive Officer of Acceleron. We’re specifically pleased with Celgene’s dedication to Acceleron as we jointly develop many promising products for the treating anemia. In conjunction with this funding, George Golumbeski, Senior Vice President of Corporate Advancement of Celgene, has became a member of the Acceleron Table of Directors.. Acceleron Pharma raises $30 million through private financing Acceleron Pharma, Inc., a biopharmaceutical company developing proteins therapeutics for malignancy and orphan illnesses, today announced it raised a $30M private funding.These outcomes provide striking proof that norepinephrine plays a critical role for the creation of desired behavioral effects of most classes of antidepressant substances including the SSRIs. Penn researchers also contributing to this study include: John F. Cryan, Olivia F. Friedland, Ming Ouyang, Bradford R. Hirsch, Michelle E. Page, Ashutosh Dalvi, and Steven A. Thomas. The scholarly study was funded by grants from america Public Health Service, The National Institute of Mental Health, The National Institute of Neurological Stroke and Disorders, and a Young Investigator Award from the National Alliance for Study on Despair and Schizophrenia. Great news for men and women dealing with exercise and diet-resistant excess fat in areas just like the tummy, love handles and back rolls!S.